Eilber F R, Grant T, Morton D L
Cancer Treat Rep. 1978 Feb;62(2):213-6.
Seventeen consecutive patients with osteogenic sarcoma participated in a prospective study to ascertain first, whether postoperative adjuvant chemotherapy or chemoimmunotherapy could reduce the incidence of distant metastases and second, whether in situ tumor cell destruction could be achieved with preoperative chemotherapy and radiation therapy. To date 14 of 17 patients (85%) are alive and free of disease for a median survival time of 11 months. Three patients developed recurrent disease, one with local recurrence in the tibia and two with pulmonary metastases. Limb salvage was attained in 12 patients by cadaver allografts and in one patient by radiation alone at 6 months.
17例骨肉瘤患者连续参与了一项前瞻性研究，目的首先是确定术后辅助化疗或化疗免疫疗法是否能降低远处转移的发生率，其次是确定术前化疗和放疗是否能实现原位肿瘤细胞破坏。迄今为止，17例患者中有14例（85%）存活且无疾病，中位生存时间为11个月。3例患者出现疾病复发，1例胫骨局部复发，2例肺转移。12例患者通过尸体同种异体移植实现了保肢，1例患者仅在6个月时接受放疗后实现了保肢。
